Supernus Pharmaceuticals SG&A Expenses 2011-2024 | SUPN
Supernus Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Supernus Pharmaceuticals Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$336 |
| 2022 |
$377 |
| 2021 |
$305 |
| 2020 |
$201 |
| 2019 |
$153 |
| 2018 |
$155 |
| 2017 |
$138 |
| 2016 |
$106 |
| 2015 |
$89 |
| 2014 |
$73 |
| 2013 |
$56 |
| 2012 |
$20 |
| 2011 |
$8 |
| 2010 |
$5 |
Supernus Pharmaceuticals Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$70 |
| 2024-06-30 |
$86 |
| 2024-03-31 |
$87 |
| 2023-12-31 |
$81 |
| 2023-09-30 |
$83 |
| 2023-06-30 |
$87 |
| 2023-03-31 |
$86 |
| 2022-12-31 |
$74 |
| 2022-09-30 |
$112 |
| 2022-06-30 |
$100 |
| 2022-03-31 |
$90 |
| 2021-12-31 |
$102 |
| 2021-09-30 |
$72 |
| 2021-06-30 |
$70 |
| 2021-03-31 |
$61 |
| 2020-12-31 |
$57 |
| 2020-09-30 |
$54 |
| 2020-06-30 |
$48 |
| 2020-03-31 |
$42 |
| 2019-12-31 |
$33 |
| 2019-09-30 |
$39 |
| 2019-06-30 |
$40 |
| 2019-03-31 |
$41 |
| 2018-12-31 |
$37 |
| 2018-09-30 |
$41 |
| 2018-06-30 |
$40 |
| 2018-03-31 |
$37 |
| 2017-12-31 |
$34 |
| 2017-09-30 |
$41 |
| 2017-06-30 |
$35 |
| 2017-03-31 |
$28 |
| 2016-12-31 |
$29 |
| 2016-09-30 |
$26 |
| 2016-06-30 |
$26 |
| 2016-03-31 |
$25 |
| 2015-12-31 |
$24 |
| 2015-09-30 |
$23 |
| 2015-06-30 |
$23 |
| 2015-03-31 |
$19 |
| 2014-12-31 |
$18 |
| 2014-09-30 |
$17 |
| 2014-06-30 |
$20 |
| 2014-03-31 |
$18 |
| 2013-12-31 |
$15 |
| 2013-09-30 |
$15 |
| 2013-06-30 |
$12 |
| 2013-03-31 |
$14 |
| 2012-12-31 |
$9 |
| 2012-09-30 |
$4 |
| 2012-06-30 |
$5 |
| 2012-03-31 |
$3 |
| 2011-12-31 |
$3 |
| 2011-09-30 |
$2 |
| 2011-06-30 |
$2 |
| 2011-03-31 |
$2 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
